Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Lefitolimod |
Synonyms | |
Therapy Description |
Lefitolimod (MGN1703) is a TLR9 agonist, which results in increased anti-tumor immune response, and may lead to decreased tumor growth (PMID: 25577571, PMID: 31741757). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Lefitolimod | MGN1703|MGN 1703|MGN-1703 | TLR9 Agonist 9 | Lefitolimod (MGN1703) is a TLR9 agonist, which results in increased anti-tumor immune response, and may lead to decreased tumor growth (PMID: 25577571, PMID: 31741757). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|